Product Information
DOXAZOSIN MESYLATE 4 MG TAB is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0834 per EA under NDC 16571016701. Its NADAC has been published 105 times since Oct 2, 2024.
FDA first approved this application on Mar 15, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
4 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571016701
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DOXAZOSIN MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA212727FDA Approved
3/15/2022
TE Code
AB
On Market Since
5/20/2024
Pharmacological Classes
Price Statistics
The NADAC for DOXAZOSIN MESYLATE 4 MG TAB has been published 105 times since Oct 2, 2024, and over the history we have for it it has declined 18.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0834 per EA |
|---|---|
| All-time high | $0.1027 (Oct 16, 2024) |
| All-time low | $0.0834 (Sep 23, 2026) |
| 52-week high | $0.0975 |
| 52-week low | $0.0834 |
| Median price | $0.0929 |
| Average price | $0.0922 |
| Largest weekly change | -9.6% (Nov 20, 2024) |
| Weeks tracked | 105 |
| Tracking since | Oct 2, 2024 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Doxazosin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
alpha-Adrenergic Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOXAZOSIN MESYLATE 4 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for DOXAZOSIN MESYLATE 4 MG TAB, manufactured by Rising Pharma Holdings Inc., is $0.0834 per EA (NDC 16571016701), effective Sep 30, 2026.
How has the price of DOXAZOSIN MESYLATE 4 MG TAB changed over time?
Over the history we have for it, the NADAC for DOXAZOSIN MESYLATE 4 MG TAB has declined 18.8%. It has been tracked across 105 weekly CMS publications since Oct 2, 2024.
What are the highest and lowest recorded NADAC prices for DOXAZOSIN MESYLATE 4 MG TAB?
Since Oct 2, 2024, the NADAC for DOXAZOSIN MESYLATE 4 MG TAB has ranged from a low of $0.0834 (Sep 23, 2026) to a high of $0.1027 (Oct 16, 2024), with a median of $0.0929 per EA.
Are there cheaper alternatives to DOXAZOSIN MESYLATE 4 MG TAB?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DOXAZOSIN MESYLATE 4 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures DOXAZOSIN MESYLATE 4 MG TAB?
DOXAZOSIN MESYLATE 4 MG TAB (NDC 16571016701) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.